07/2012. UROMUNE study
It has been published in the International Urogynecology Journal an interesting clinical study showing the advantages of UROMUNE over the conventional antibiotherapy treatment in patients suffering recurrent cystitis.
The study, directed by Dr. M.F. Lorenzo (Salamanca University Hospital), was performed with a total of 319 patients, 159 of them receiving the vaccine. Both the number of infections and positive urocultures were significantly lower in those patients treated with UROMUNE as compared with those treated with antibiotics. UROMUNE is manufactured by Inmunotek and promoted in Spain by QPharma.
Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics
M. F. Lorenzo-Gómez, B. Padilla-Fernández, F. J. García-Criado, J. A. Mirón-Canelo, A. Gil-Vicente, A. Nieto-Huertos, J. M. Silva-Abuin
1. Servicio de Urología, Complejo Asistencial Universitario de Salamanca, Paseo San Vicente 58-182, Instituto de Investigación Biomédica de Salamanca, 37007, Salamanca, Spain
2. Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain
3. Departamento de Medicina Preventiva y Salud Pública, Universidad de Salamanca, Salamanca, Spain
4. Medicina de Familia y Comunitaria del Complejo Asistencial de Zamora, Universidad de Salamanca, Salamanca, Spain